Research and Development

Ablynx has revealed that its interleukin 6 pathway via its IL-6 receptor (IL-6R) vobarilizumab failed to meet its primary endpoint …

There are good reasons to think exiting the EU represents a major opportunity for this dynamic and world-leading industry, argues …

Roche has revealed further data from its Phase 3, IMpower150 study, which showed that a combination of Tecentriq and Avastin, …

As me move startlingly quickly towards Easter, it’s time for another Top Ten rundown. This week, Celgene surprised the industry …

A team of researchers at Chicago’s University of Illinois (UIC) have revealed that their promising drug which could prove an …

The controversial and much-discussed “right to try” bill has been passed in the US House of Representatives, quickly rebounding after …

Coming on the back of a Regeneron research piece published in the New England Journal of Medicine, the company announced …

An independent report, entitled Brexit – Medicines, Medical Devices and Substances of Human Origin and written by the Health and …

NICE has announced that it has recommended against the use of Dompe’s recombinant human nerve growth factor eye drop therapy …

Japan’s biggest pharmaceutical firm Takeda has announced the completion of construction of its new global headquarters in the country’s capital …

Johnson & Johnson have revealed that its Chief Financial Officer and Executive Vice President, Dominic J. Caruso, will retire from …

Celgene has gone against industry movement to back out of the neuroscience area by putting down a potential $2.2 billion …

Heron Therapeutics has been buoyed by the news that its painkiller agent HTX-011 met all of its primary and secondary …

Regeneron has confirmed that its vascular endothelial growth factor (VEGF) inhibitor injection Eylea (aflibercept) met its primary endpoint in a …

Roche’ Tecentriq needs a big result in the immunotherapy space – it initially burst onto the scene as a third-to-market …